Bill.com Shares Gain As Analysts Cheer Its Q4 Performance
Bill.com Holdings, Inc (NYSE: BILL) clocked 156% revenue gr
Tapestry’s Outlook Offers ‘An Encouraging Sign,’ Says This Analyst
Telsey Advisory Group analyst Dana Telsey reiterated an Outperform rating on Tapestry Inc (NYSE:TPR) with a price target of $46.00. The analyst said…
Kohl’s Has ‘Competitive Advantages’ Via Full-Family Offering, Says This Analyst
Telsey Advisory Group analyst Dana Telsey reiterated a Market Perform rating on Kohl’s Corp (NYSE:KSS) with a price target of $35.00. The analyst…
Estee Lauder’s Conservative Annual Guidance ‘Expected,’ Says This Analyst
Telsey Advisory Group analyst Dana Telsey reiterated an Outperform rating on Estee Lauder Companies Inc (NYSE:EL) with a price target of $377.00. The…
Cisco Systems Rallies Off Q4 Earnings: 4 Analysts Break Down The Print
Cisco Systems Inc (NASDAQ: CSCO) reported quarterly earnings of 83 cents per share, beating the consensus estimate by 1 cent per share, on revenues of $13.1 billion, ahead of the Street expectations o
4 Analyst Takeaways From Target Earnings
Target Corporation (NYSE: TGT) reported second-quarter revenues of $26.04 billion — just shy of a consensus estimate of $26.09 billion. Adjusted earnings were 39 cents per share, missing expectations of 73 cents per share.
Analysts Remain Cautious On Tremor Despite Its Tailwinds, Cut Price Target By 15%
Analysts cut their estimates and price targets on Tremor International Ltd (NASDAQ: TRMR) over a softer outlook amid a challenging macro environment.
4 Walmart Analysts Raise Price Targets After Q2 Earnings Beat: ‘Leader And Market Share Gainer’
Walmart Inc (NYSE: WMT) shares traded higher Wednesday after the discount retailer reported impressive second-quarter earnings growth and reiterated its full-year guidance.
Analysts Expressed Optimism Over Autodesk’s Upcoming Results Citing Robust Demand, Digitization, Easing Macros
Mizuho analyst acknowledged that several significant large-cap software vendors are due to report July quarter results over the next few weeks. Following an extended sell-off, software and the broader market have significantly rallied in recent weeks.
Sanofi Earns Price Target Cut After Stopping Breast Cancer Drug Trial
Sanofi SA (NASDAQ:SNY) discontinued the development of its oral SERD amcenestrant following a negative interim analysis of the AMEERA-5…